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INTRODUCTION 
Diffuse large B-cell lymphoma (DLBCL) constitutes 25-30% of adult non-Hodgkin 
lymphomas in western countries. The incidence of DLBCL has largely increased in 
these last decades, particularly in older populations; it affects more frequently males and 
the median age at presentation is in the 7
th
 decade. R-CHOP (Rituximab, 
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) is at present the standard 
therapy for DLBCL, yielding to complete response rate of nearly 70-80% and 5 years 
progression free survival of 50 to 90% according to initial prognostic risk. The 
prognosis of patients with DLBCL relapsed and/or refractory to CHOP-R first line 
therapy is dismal. High dose therapy and autologous stem cell transplant (ASCT) is an 
active rescue therapy in nearly 50% of patients with chemo-sensitive disease. Therapy 
of patients who relapse after ASCT or result non eligible for ASCT because of 
refractory disease, age or co-morbidities, represents an unmet medical need.  
Histone deacetylases (DACs) are involved in chromatin structure regulation and 
function. Treatment with DACs inhibitors leads to the activation or repression of genes 
regulating apoptosis, proliferation, differentiation, angiogenesis, immune responses. 
These agents resulted to be active for the treatment of T and B-cell lymphoma and other 
haematological malignancies. Previous in vitro studies underlined the possible 
pathophysiological role of DACs in diffuse large B-cell lymphoma (DLBCL)(1-6). 
Panobinostat is a potent pan-DACs inhibitor belonging to cinnamic hydroxamic acid 
class of compounds. It is highly potent class I/II pan-DAC inhibitor that has shown anti-
tumor activity in pre-clinical model and in cancer patients. 
In t  s r   r   t      Fon  z on  It l  n  L n om     s  n     p  s  II  l n   l tr  l 
aiming to assess the efficacy and the safety of the HDACi Panobinostat in DLBCL 
patients refractory to conventional therapies (Study ID: IIL _ PanAL10). The present 
research project will be performed within this clinical trial. 
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1. OVERVIEW OF DIFFUSE LARGE B CELL 
LYMPHOMA 
1.1. Definition and incidence 
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in 
adults. The annual incidence of Non-Hodgkin's Lymphomas (NHL) is estimated to be 
15–20 cases/100,000 (7) Based on the data of the International NHL study group (Non-
Hodgkin's Lymphoma classification Project 1997) (8) and the WHO Classification of 
Tumour of Haematopoietic and Lymphoid Tissues (9), DLBCL accounts for 
approximately 31% of all NHL in Western Countries and 37% of B-cell tumours 
worldwide. The median age of DLBCL falls between the sixth and seventh decade, 
although other types of aggressive NHL present at a lower median age, as for instance 
Burkitt lymphoma and primary mediastinal lymphoma. DLBCL corresponds to a group 
of lymphoid malignancies composed of large cells with vesicular nuclei, prominent 
nucleoli, basophilic cytoplasm and a usually high proliferation rate. As acknowledged in 
the 2008 WHO Classification  (9) morphological, biological and clinical studies have 
allowed the subdivision of DLBCLs into morphological variants, molecular and 
immunophenotypic subgroups and distinct disease entities. However, a large number of 
cases still remain biologically heterogeneous, for which there are no clear and accepted 
criteria for subclassification: these are collectively termed DLBCL, not otherwise 
specified (NOS). Importantly, the principles used for the present organization of 
DLBCLs are the ones established in 1994 by the Revised European American 
Lymphoma (REAL) Classification (10) and subsequently adopted in the third and fourth 
editions of the WHO Classification (9) in which each lymphoma entity is defined by the 
amalgamation of clinical data, morphology, phenotype, cytogenetics, and molecular 
characteristics as well as by the identification of a normal counterpart. 
1.2. Classification 
DLBCLs are defined as a heterogeneous group of malignancies composed of large cells 
with nuclei at least twice the size of a small lymphocyte and usually larger than those of 
tissue macrophages. They more often occur de novo but can also represent the 
progression or transformation of a less aggressive B-cell neoplasm, such as chronic 
lymphocytic leukaemia, lymphoplasmacytic lymphoma, marginal zone lymphoma, 
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follicular lymphoma and even lymphocyte predominant Hodgkin lymphoma. DLBCL 
can develop at either nodal or extra-nodal sites. In the fourth edition of the WHO 
Classification of Haematopoietic and Lymphoid Tumours (9), they have been 
subdivided into four categories, some of which not quoted in previous schemes: (a) 
DLBCL – not otherwise specified (DLBCL, NOS), (b) DLBCL with predominant 
extranodal location, (c) large cell lymphoma of terminally differentiated B-cells, and (d) 
borderline cases. Each category further includes morphologic and/or clinico-pathologic 
variants that make the organization of these neoplasms quite complex. In the following, 
we focus on the most frequent subgroup: DLBCL, NOS.  
1.3. DLBCL, NOS 
1.3.1 Morphology 
DLBCL NOS is the most common form of NHL. It usually consists of a mixture of 
centroblasts and immunoblasts that grow diffusely, partly or completely effacing the 
normal structure of the involved organ(s). Centroblasts are defined as large cells with a 
central oval-round nucleus, finely dispersed chromatin, multiple small nucleoli at times 
adjacent to the nuclar membrane, and a moderate rim of basophilic cytoplasm. 
Immunoblasts have instead a slightly eccentric nucleus, one or more prominent nucleoli 
(sometimes with an inclusion-like appearance), and a rather large rim of basophilic 
cytoplasm with a more or less pronounced Golgi area (11). Features of intrasinusoidal 
spread are occasionally observed. The number of mitotic figures is globally high, the 
amount of reactive T-lymphocytes and/or histiocytes variable. In any case, the latter do 
not overwhelm the neoplastic population as instead observed in the so-called 
histiocyte/T-cell-rich B-cell lymphoma (HTCRBCL). In 10–15% of cases, one cytotype 
predominates over the other, representing more than 90% of the examined population: 
t  s    s s  r  r sp  t v ly r   rr   to  s “  ntrobl st  ” or “ mmunobl st  ”. T   l tt r 
may show aspects of plasmacellular differentiation, making the differential diagnosis 
with extra-medullary involvement by plasmablastic lymphoma or poorly differentiated 
plasma cell myeloma possibly difficult. A recent study has suggested that pure 
immunoblastic morphology does represent a negative prognostic indicator more 
relevant than the various immunohistochemical algorithms proposed during the last few 
years (12) Other morphologic variants are the multilobated and anaplastic large cell 
ones. The former may be observed in tumours arising at extranodal sites, especially the 
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bone, while the latter resembles T-cell anaplastic large cell lymphoma with Reed–
Sternberg-like elements, intrasinusoidal diffusion and cohesive growth pattern but 
differs from it because of the phenotype, cytogenetics and, last but not least, definitely 
worse clinical course. 
1.3.2 Phenotype 
On  mmuno  sto   m stry  t     lls o  DLBCL  NOS  r  SI +/−  CI −/+  n   xpr ss 
B-cell-associated antigens (CD19, CD20, CD22, and CD79a) (11). In particular, CD20 
is relevant not only on diagnostic grounds but also for therapeutical purposes, being the 
target of the Rituximab humanized monoclonal antibody that has dramatically improved 
the prognosis of these neoplasms. DLBCL are usually CD45+ and PAX5+: the search 
for such molecules can, however, be negative in case of pronounced plasmacellular 
differentiation, producing strong positivity for BLIMP-1, CD138 and CIg. CD10, 
BCL6, IRF4, LMO2, GCET1, and FOXP1 are variably expressed: their combination 
has represented the base for the construction of algorithms aiming to surrogate gene 
expression profiling (GEP) results (13), (14) and (15). Cases with anaplastic 
morphology typically express CD30, while those possibly derived from marginal zone 
or monocytoid B-cells more often turn IRTA-1 positive. Recently, attention has been 
paid to CD5 positivity (16). This occurs in the absence of cyclin D1 over-expression, a 
fact that allows the easy differentiation of CD5
+
 DLBCLs from polymorphic MCLs 
(17). Finally, additional useful markers are BCL-2, p53 and Ki-67 as well as the NF-kB 
components (RELA, RELB, REL, p50 and p52) and EBER in situ hybridization 
(ISH) (18). BCL-2 is expressed by about 50% of DLBCL of either the ABC type (see 
below) or carrying t(14;18) as shown by fluorescent ISH (FISH). The latter condition is 
not invariably due to FL transformation (see below). BCL-2 protein expression – that is 
down-regulated in normal GC where apoptosis plays a critical role in negative B-cell 
selection – is associated with an inferior outcome in DLBCL irrespective of the 
mechanism causing it (18) and (19). P53 positivity may be found in the setting of 
DLBCL derived from a less aggressive B-cell neoplasm (e.g. Richter's syndrome and 
related conditions in patients with chronic lymphocytic leukaemia) (12). Ki-67 marking 
is representative of the proliferation rate: in case it exceeds the 90% value, FISH 
analysis may be worthy to identify tumours carryingMYC complex karyotype (see 
below). On the same line, EBER ISH allows the recognition of EBV-infected DLBCL, 
which are not infrequently encountered in immunocompromised individuals (e.g. due to 
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AIDS or immunosuppressive therapies such as the ones following transplantation) (9). 
Last but not least, the search for the NF-kB components is indicative of the status of the 
canonical or alternative pathway, a fact that is provided with potential therapeutic 
implications (20;21). 
Besides the above mentioned markers that refer to attributes of the neoplastic cells, 
other molecules may be prognostically relevant that correspond to different 
microenvironmental components (e.g.: CD68, FOXP1, CD21 and CD31). 
1.3.3. Genetics 
Genetic alteration may relate to: 
 Antigen receptors genes: clonal reengagement of Ig encoding genes is generally 
recorded. By adopting the highly reliable BIOMED-2 approach, combined 
application of IGH (VH–JH and DH–JH) and IGK tubes is recommended in 
order to detect virtually all rearranged cases, in the light of the high levels of 
somatic mutations characteristic of DLBCL (12); 
 Aberrant somatic hypermutations: these are detected in more than 50% DLBCL 
and affect multiple genes, including PIM-1, MYC, Rho/TTF andPAX5. They are 
thought to contribute to the oncogenesis of the tumour (12); 
 Genetic aberrations: chromosomal translocations of band 3q27 are detected in 
30–40% of cases and cause the rearrangement of BCL-6, a transcriptional 
repressor selectively expressed by germinal centre (GC) B-cells and controlling 
GC formation (22,23,24) . The translocation inhibits the down-regulation 
of BCL-6 that is required for further differentiation of GC B-cells, and creates a 
DNA error prone GC microenvironment by functionally inactivating 
p53 (25,26). Translocation of the BCL2 gene, i.e. t(14;18), a hallmark of FL, 
occurs in approximately 20% of DLBCL arising de novo and in most cases 
transformed from a prior follicular phase (27). A MYCrearrangement is observed 
in up to 10% of an unselected series of cases (28)  and is usually associated with 
a complex pattern of genetic alterations (29). The MYC break partner is an Ig-
gene in 60% and a non-Ig-gene in 40% of cases (29) Approximately 20% of 
cases with a MYC break have a concurrent IGH-BCL2 translocation 
and/or BCL6 break or both (29) and (30). These cases usually have a high 
prol   r t on (>90% K 67+)  n  m y b  b tt r   t  or z    s “B-cell 
lymphomas, unclassified with features intermediate between diffuse large B-cell 
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lymp om   n  Burk tt lymp om ” (31). Other rare molecular lesions 
occasionally involved in DLBCL pathogenesis include translocations of BCL-
8 and MUC-1, amplification of REL, and inactivation of the p53tumour 
suppressor gene (32). A recent study has identified monoallelic deletions and 
mutations inactivating CREBBP and EP300 in nearly 39% of GCB-DLBCL and 
less frequently in ABC–DLBCL (17% of samples) 
(33). CREBBP and EP300 are acetyltransferases that act as transcriptional co-
activators in multiple signalling pathways. As a consequence of the 
mutations, CREBBP/EP300 lose their ability to acetylateBCL-6 and p53, a post-
translational modification that inactivates BCL-6 by disrupting the recruitment 
of histone deacetylases (HDACs) and thus hindering its capacity to repress 
transcription, while representing an essential requirement for p53 activation 
(34 ) and (35). Thus, CREBBP and EP300 mutations may contribute to 
lymphomagenesis by favouring the decreased activity of the tumour suppressor 
and constitutive activation of the oncogene (33). Interestingly, these mutations 
are also found in about 40% of FL, suggesting that DLBCL and FL share 
common pathogenetic events (33). Chromosomal translocations juxtaposing the 
IRF4 oncogene next to one of the immunoglobulin loci were recently identified 
as a novel recurrent aberration in mature B-cell lymphoma, predominantly GCB-
type DLBCL and FL (36). These lymphomas shared strong expression of 
IRF4/MUM1 and BCL6, and lacked PRDM1/BLIMP1 expression 
and t(14;18)/BCL2 breaks. The GEP of IG/IRF4-positive lymphomas differs 
from other subtypes of DLBCL, and IG/IRF4 positivity is associated with young 
age and a favourable outcome. IRF4 translocations may be primary alterations in 
a subset of GCB-derived lymphomas. The probability for this subtype of 
lymphoma significantly decreases with age, suggesting that diversity in tumour 
biology might contribute to the age-dependent differences in prognosis of 
lymphoma. 
1.4.  Staging 
A diagnosis of DLBCL cannot be established without the examination of tissue 
obtained at biopsy. Excisional biopsy is mandatory for DLBCL diagnosis; while core 
needle biopsy should be performed only in the case other surgical approaches are 
possible. On the basis of the lymphoma presentation, the biopsy can be performed on 
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enlarged superficial lymph node or on lymphoid tissue in Waldeyer's ring or on 
mediastinal adenopathy by core needle biopsy, mediastinoscopy or 
mediastinotomy (37)] or on retroperitoneal adenopathy by ultrasound-guided core 
needle biopsy, laparoscopy or laparotomy (38). Once the diagnosis has been established 
the first critical step is the pre-treatment evaluation and staging. 
The standard staging system used for DLBCL was proposed at the Ann Arbor 
Conference in 1971 (39) and the Cotswlds modification (40). This staging system 
reflects the number of sites of involvement and their relation to the diaphragm, the 
existence of B symptoms (fevers >38 °C for at least three consecutive days, night 
sweats, body weight loss >10% during the 6 months prior to diagnosis) and the presence 
of extranodal disease. A careful history and physical examination are the most 
important factors in the patient's evaluation. Physical examination includes evaluation 
of all lymph node enlargement, recording site and size of all abnormal lymph nodes, 
inspection of Waldeyer's ring, evaluation of the presence or absence of 
hepatosplenomegaly, inspection of the skin, and detection of palpable masses. The 
presence or absence of B symptoms should be noted, and other symptoms may show 
specific sites of involvement. An assessment of performance status according to the 
ECOG scale is important in all patients, and especially for those entering into clinical 
research trials. 
Laboratory studies that should be routinely performed in NHL patients include a 
complete blood count to assess bone marrow reserves and a white blood cell differential 
with careful examination of the peripheral blood to look for the presence of circulating 
lymphoma cells. Serum chemistry should include an assessment of hepatic and renal 
function. Lactic dehydrogenase (LDH) is also an important indicator of tumour activity 
and is included in the International Prognostic Index (41). The uric acid level may 
predict patients at increased risk for urate nephropathy. A test for a complete assessment 
of HIV, HBV, and HCV should be performed in all patients. 
A bone marrow aspirate and biopsy should be performed in all patients. Bilateral bone 
marrow biopsies have been recommended because they increase sensitivity of detection 
of NHL involvement by 10–20%. However, an adequate (>2 cm) unilateral bone 
marrow specimen is generally sufficient. Additional testing in DLBCL may include 
lumbar puncture to assess liquor cytology identifying subclinical meningeal 
involvement and brain MRI in patients with high risk of central nervous system (CNS) 
progression. 
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Fluorodeoxyglucose Positron Emission Tomography (PET) is now a standard 
procedure both for staging and response assessment. Many studies showed that PET at 
the end of treatment is highly predictive of PFS and OS in aggressive lymphomas with 
or without residual masses detected with CT scan. PET scan is able to distinguish 
between lymphoma and necrosis or fibrosis in residual masses. The combination of 
International Workshop Criteria (IWC) and PET was evaluated in a retrospective 
analysis of 54 patients with NHL. On the basis of this study, the International 
Harmonization Project has provided new recommendations for response criteria for 
aggressive malignant lymphomas, incorporating PET into the definition of response at 
the end of treatment (42;44). PET scan should not be used in follow-up setting, mostly 
due to a high rate of false positives and the fact that its increased sensitivity does not 
translates into clinical benefit. Further studies are warranted to investigate the cost 
effectiveness and the benefit of using PET during the follow up phase. 
1.5. Prognosis 
Each DLBCL category and their morphologic and/or clinico-pathologic variants exhibit 
varied clinical presentation, behaviour and treatment sensitivity. Regarding DLBCL–
NOS, it occurs in adult patients, with a median age in the seventh decade, but the age 
range is broad, and it may also occur in children. Clinical presentation, behaviour and 
prognosis of DLBCL–NOS are variable, depending mainly of the extranodal site when 
they arise. Patients most often have a rapidly enlarging, often asymptomatic, mass at a 
single nodal or extranodal site; up to 40% of presentations regard an extranodal organ. 
These malignancies present in localized manner in approximately 20% of patients. 
Disseminated extranodal disease is less frequent, and one third of patients have systemic 
symptoms. Overall, DLBCLs are aggressive but potentially curable malignancies. Cure 
rate is particularly high in patients with limited disease with a 5-year progression free 
survival (PFS) ranging from 80% to 85%. Patients with advanced disease or 
symptomatic disease have a 5-year PFS ≈ 50%. Prognostic factors in DLBCL can be 
divided into those related primarily to the patient (e.g. age and performance status), 
those related to the tumour itself (e.g. stage, tumour burden, proliferating fraction, 
extranodal involvement), those related to aggressiveness indicators (e.g. LDH serum 
level, β2-microglobulin levels, proliferating fraction), and those related to the 
therapeutic strategy. Some extranodal sites, like brain (45) or testis (46), require special 
treatment strategies, and DLBCLs arisen in these organs constitute particularly entities 
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with poor prognosis. Response rate after primary treatment is highly predictive of 
outcome. 
The International Prognostic Index (IPI) and age-adjusted International Prognostic 
Index (aaIPI) have been developed as models for predicting outcomes based on clinical 
factors from more than 4000 patients ( Table 1) (41). The models proved to be more 
accurate than the Ann Arbor classification in predicting survival. The aaIPI, which 
includes stage, LDH and performance status, is the most commonly used in clinical 
practice and it is helpful in stratifying patients below or over 60 years of age. A revised 
version has been developed in the post-rituximab era (R-IPI) (47). The IPI has been 
documented to be robust in different series of DLBCL and still represents the only 
benchmark of DLBCL prognosis, even in the rituximab era ( Fig. 1) (48). 
 
 
Table 1. 
 
 
International Prognostic Index (IPI) for DLBCL. 
aa-IPI, age-adjusted International Prognostic Index; ECOG, Eastern Cooperative Oncology 
Group; IPI, International Prognostic Index; R-IPI, revised International Prognostic Index. 
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Fig. 1.  
 
 
                                   R-IPI: Risk groups in DLBCL in the rituximab era. 
 
Many biological parameters directly related to the tumour but also eventually to the 
host, have been identified as prognostic factors in DLBCL. This represents an exciting 
field of understanding of the disease and for designing of new therapeutics options, but 
the use of these factors for treatment decisions remains investigational. GEP of the 
malignant cells and their microenvironment is the most interesting procedure to reveal 
biological heterogeneity in DLBCL. Distinct subsets, including germinal-centre-like 
(GC) and activated B-cell-like (ABC) DLBCL, have been identified as having different 
genetic markers, activation pathways, and clinical outcomes (49;51). CD10, BCL-6, and 
MUM1 immunohistochemistry have been found to be potential surrogates for the gene 
expression profiles, having similar predictive capabilities (52). Currently, further 
investigation is needed before GEP or immunohistochemistry is applicable to clinical 
practice. However, some preliminary studies suggest that certain drugs are more active 
in one of the GEP subgroups of recurrent DLBCL and not in the other (53). A recently 
reported retrospective study showed that salvage therapy with lenalidomide is 
associated with a significantly higher response rate in ABC–DLBC with respect to 
GCB-cell-DLBCL (54). More solid confirmation on the prognostic value of these 
markers in large prospective trials is attended  
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1.6. Treatment 
The choice of the first-line treatment for patients with DLBCL is based on the 
individual IPI score and age. Therefore, three major subgroups of DLBCL patients 
should be considered: elderly patients (>60 years, aaIPI = 0–3); young patients with low 
r sk (≤60 years, aaIPI = 0–1); youn  p t  nts w t       r sk (≤60 years, aaIPI = 2–3). 
1.6.1. Treatment of elderly patients 
The addition of the anti-CD20 monoclonal antibody rituximab to CHOP chemotherapy, 
administered every 14 or 21 days, is the standard treatment for elderly patients with 
DLBCL on a type 1 basis. A p  s  III stu y o  Group   ‟ Etu     s Lymp om s    
l‟A ult  (GELA) r n om z   399 pr v ously untr  t   p t  nts w t  DLBCL, 60–
80 years old, to receive either 8 cycles of CHOP every 3 weeks (CHOP21) or 8 cycles 
of CHOP21 plus rituximab (55). Complete response (CR) rates, 2-year OS and Event-
Free Survival (EFS) were significantly better in the R-CHOP arm without increase of 
adverse events. A recently updated follow-up analysis confirmed that the superiority of 
R-CHOP was maintained over time and the benefit was for all IPI subgroups (56,57). 
These figures are similar to those reported in a large retrospective study of the British 
Columbia University (58). 
The real impact on survival of a dose-dense regimen in elderly patients with DLBCL 
remains a matter of debate. The German High-Grade Non-Hodgkin's Lymphoma Study 
Group (DSHNHL) have shown a survival improvement with a dose-dense programme 
as CHOP every 2 weeks (CHOP14) compared to CHOP21 in the NHL-B2 trial. This 
prospective randomized trial compared 6 cycles of CHOP-21, CHOP-14, CHOEP-21 
and CHOEP-14 (bi-weekly) in a 2 × 2 factorial study design in patients older than 
60 years showing that dose dense CHOP-14 significantly improved PFS and OS over 
the others (59). The following study conducted by the DSHNHL (RICOVER 60 trial) 
randomized 1222 patients to receive six or eight courses of CHOP14 with or without 
rituximab plus radiotherapy (RT) to sites of initial bulky disease (60). Six cycles of R-
CHOP14 with 8 doses of rituximab significantly improved EFS, PFS, and OS over 6 
cycles of CHOP-14 treatment (3-year OS: 78.1% vs. 67.7%). Moreover, no advantages 
were reported with the addition of 2 further courses of chemotherapy suggesting that 
response-adapted addition of chemotherapy beyond six cycles, though widely practiced, 
is not justified. 
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The optimal administration schedule of rituximab remains to be defined. Rituximab 
serum levels build up slowly after infusion and it may be that also dose dense 
 mmunot  r py m y  mprov  t          y o  t   tr  tm nt. T us  t   p  s  II “D ns -
R-CHOP-14” tr  l  xplor    n  l  rly p t  nts  w t  suppl m nt    os   nt ns  
rituximab during the first 2 cycles of R-CHOP14, maintaining a single dose in the 
subsequent cycles for a total of 12 doses of rituximab delivered in 6 courses of 
chemotherapy. One hundred patients were recruited, the results historically compared 
with those achieved in RICOVER 60 study, showed a markedly increase in rituximab 
serum level and suggested a higher efficacy in High-risk IPI patients (1-year EFS 74% 
vs. 65%) but an increased incidence of infection, mainly interstitial pneumonia, was 
also reported (61). This strategy is currently being compared with 8 doses over 2 week 
application (both in R-CHOP14 × 6 regimen) in a controlled randomized DSHNHL 
study. 
A superiority of R-CHOP14 over R-CHOP21 has not been yet shown in randomized 
trials. Trials comparing R-CHOP21 with R-CHOP14 have been completed by the 
GELA in elderly patients (62), and by the British National Lymphoma Investigation 
(BNLI) in all age and IPI risk patients with DLBCL (63). The preliminary results of 
both trials did not show statistically significant differences for PFS and EFS between R-
CHOP21 × 8 and R-CHOP14 × 6. However, in the French study many patients did not 
receive adequate supportive measures, such as prephase treatment and G-CSF 
administration, which are necessary to maintain an adequate dose-intensity when giving 
R-CHOP14 to elderly patients. In the British trial, the inclusion criteria were extended 
also to low-risk young patients with a potential risk of reducing the statistical power of 
the trial for high risk IPI and elderly patients. Hopefully, the final results of these and 
other randomized trials will clarify this issue. 
1.6.2. Treatment  of young patients with low-risk IPI 
Following the outcome improvement observed in elderly patients, R-CHOP has been 
investigated also in younger patients. The retrospective study at the British Columbia 
University confirmed a significant improvement of OS and PFS also in patients of 
age < 60 years when rituximab was combined with CHOP compared to historical 
controls treated with CHOP alone (58) The benefit of rituximab in low-risk young 
patients has been also confirmed in a phase III multicentric study conducted by the 
Mabthera International Trial Group (the Mabthera International Trial – MInT). 
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Rituximab was combined with CHOP 21 or CHOP-like regimens (R-Chemo) and 
compared to the same chemotherapy regimens but without rituximab (chemo). Patients 
receiving R-chemo had a significantly better CR rate, and longer 3-year EFS and 
OS (64). No difference was demonstrated between R-CHOP21 and more intensive R-
CHOP-like regimens (R-CHOEP-21, R-MACOP-B). This trial was recently updated, 
confirming significant better 6-year EFS and OS of R-Chemo over Chemo (64). The 
results of this trial support the use of six cycles of R-CHOP21 as standard therapy in 
younger patients with low IPI risk DLBCL on type 1 basis. The MInT trial has also 
identified two distinct prognostic sub-groups of patients with low IPI risk defined as 
favourable (i.e. IPI = 0 without bulky disease) or less-favourable (i.e. IPI = 1 or bulky 
disease, or both). The favourable group showed a significant better 6-year PFS 
compared to less-favourable group (89.5% vs. 76.7%, respectively) (64). In attempt to 
improve lymphoma-free survival in the less-favourable group, the GELA has conducted 
a randomized phase III trial that compared a dose-dense R-ACVBP to a conventional R-
CHOP21. The preliminary results showed that the dose-dense R-ACVBP was 
associated with significant improvement in 3-year EFS, PFS and DFS, but increased 
haematological toxicity and mucositis were also reported. These results should be 
confirmed after a longer follow-up and compared to the updated 6-year results of R-
CHOP21 of the MInT trial. In fact, recently updated MInt follow-up suggests that 
radiotherapy of bulky lesions could play a central role in the management of young 
patients with IPI = 1 DLBCL (65). Thus, R-ACVBP without radiotherapy or 6 courses 
of R-CHOP21 with radiotherapy to bulky disease could be proposed to these patients. A 
randomized phase III trial of the DSHNHL group (the UNFOLDER trial) who compare 
R-CHOP 14 to R-CHOP21 is ongoing and until those results will be available, R-
CHOP21 will remain the standard regimen for the less favourable group. In the 
favourable group, considering the optimal survival rate obtained with six cycles of R-
CHOP21, a reduction of the chemotherapy regimen is under investigation in a 
DSHNHL randomized phase III study (the FLYER trial). 
1.6.3. Treatment  of young patients with high-risk IPI 
These patients have a poor outcome and represent probably the greatest current 
challenge in treating DLBCL. Around 30% of these patients develop refractory disease 
(progressing during first-line therapy or relapsing within one year). In the pre-rituximab 
era, consolidation with high-dose chemotherapy supported by autologous stem cell 
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transplant (HDC/ASCT) was employed in attempt to decrease relapse rate, but reported 
results were controversial in several randomized trial (68-72). Two meta-analyses on up 
to 11 randomized trials showed a similar OS in patients receiving first-line HDC/ASCT 
or standard chemotherapy. On the basis of observations, HDC/ASCT is not 
recommended as intensification/consolidative therapy for patients with newly diagnosed 
high-risk DLBCL outside a clinical trial. The routine use of HDC/ASCT is actually 
recommended as standard treatment only in young patients (<65 years) with DLBCL 
who did not achieve CR after first-line chemotherapy or in patients with chemosensitive 
DLBCL at relapse on type 1 basis (73). 
Several non-randomized phase II studies incorporating rituximab into dose-dense or 
dose-intense regimens as R-CHOP14 or R-CHOP14-like (R-ACVBP, R-CHOEP) 
showed that such approaches are feasible and effective in high-risk young DLBCL 
patients. An Italian trial showed the feasibility of R-CHOP14 with pegfilgrastim support 
in 50 patients with newly diagnosed aggressive lymphoma with a relative dose intensity 
of 95% and a low incidence of febrile neutropenia (74). The estimation of the outcome 
of young high-risk patients treated with dose-dense or dose-intense schemes plus 
rituximab and without ASCT is difficult, it reports a 2–5 year PFS that did not exceeded 
45–61%. These results indicate that there is a place for an HDC/ASCT strategy 
combined with dose-dense or dose-intense schemes in those high-risk groups of patients 
that are unlikely to be cured by standard R-CHOP (74;75). 
The combination of rituximab with dose-dense chemotherapy and HDC/ASCT has been 
explored in 94 untreated poor risk young DLBCL (aa-IPI score 2–3) in a prospective 
phase II Italian trial. In this group of patients a CR was obtained in 82% of patients with 
a 4-year FFS and OS of 73% and 80% respectively (76). Similar results were presented 
in a case controlled study comparing a dose dense rituximab-ACVBP followed by 
ASCT (77). A summary of the most recent studies in poor-prognosis DLBCL treated 
with (rituximab) dose-dense chemotherapy with or without HDC/ASCT. These studies 
suggest that rituximab-dose-dense chemotherapy supplemented with HDC/ASCT may 
be effective in young DLBCL patients with a poor prognosis. However, the issue if 
rituximab-HDC/ASCT may be more effective compared with rituximab-dose-dense 
chemotherapy alone in these patients will be addressed only by randomized phase III 
trials that are currently ongoing into the major cooperative groups. The preliminary 
results of two of these randomized trials were recently reported. In the randomized 
phase II trial of the DSHNHL, which compares a dose-dense R-CHOEP14 to a dose-
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escalated R-CHOEP plus HDC/ASCT, there were no statistical differences in PFS and 
OS but a significant better EFS with a lower haematological toxicity in the conventional 
arm (78). Also in a French cooperative randomized trial, the arm with intensified dose-
dense regimen plus R-HDC/ASCT failed to demonstrate a significant benefit of 
lymphoma-free survival over a standard R-CHOP14 (79). The SWOG and the Italian 
Lymphoma Intergroup recently completed two randomized trials assessing the role of 
R-HDC and ASCT in younger high-risk (aaIPI = 2–3) DLBCL patients. The SWOG 
S9704 trial has investigated the role of HDC/ASCT as part of first-line treatment in 
patients with stage II–IV aggressive lymphoma, bulky disease and high-
intermediate/high IPI in first remission after 5 cycles of CHOP ± R (80). Three hundred 
ninety-seven patients up to age 65 have been enrolled between 9/97 and 12/07 and 
induced with 5 cycles of CHOP (n = 215) or CHOP-R (n = 182); patients with complete 
or partial response (n = 253) have been randomly allocated to an additional course of 
CHOP ± R followed by autotransplant using TBI- or BCNU-based regimens (n = 125 – 
experimental arm) or to additional three courses of CHOP ± R (n = 128 – control arm). 
Experimental arm has been associated with a significantly better 2-year PFS (69% vs. 
56%;p = 0.005), with no benefit in OS (2-year: 74% vs. 71%; p = 0.32). Only patients 
with high IPI achieved OS benefit after HDC/ASCT, with a 2-year OS of 82% and 64% 
respectively for experimental-arm and control-arm subgroups (80). Although the 
SWOG S9704 trial seems to support a role for upfront HDC/ASCT in patients with 
advanced DLBCL and high IPI grade, it is important to underline that accrual was long 
l st n  (≈10 years), 54% of patients did not receive rituximab and several patients with 
histotypes other than DLBCL have been enrolled, with the potential introduction of 
relevant interpretation biases. In the Italian study (the DLCL04 trial) a full course of 
rituximab-dose-dense chemotherapy (R-CHOP14 or R-MegaCHOP14) alone was 
compared with the same rituximab-dose-dense chemotherapy followed by R-
HDC/ASCT. Preliminary results of DLCL04 trial showed that upfront HDC/ASCT 
significantly reduces relapse rate in comparison to R-CHOP14 in young patients with 
high-risk DLBCL, but this PFS advantage did not translate into OS improvement (81). 
A longer follow-up will further clarify the role of first-line HDC/ASCT in these poor-
prognosis patients. Considering preliminary results of the four randomized trials 
performed in the rituximab era (79;81), HDC/ASCT should not be used as upfront 
treatment for young high-risk patients outside prospective clinical trials. 
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1.6.4 Treatment of relapsed or refractory disease 
Patients with DLBCL who experience relapse or fail to achieve CR after first-line 
therapy have a poor outcome. The wide use of front-line rituximab-containing 
chemoimmunotherapy regimens has been associated with a substantial reduction in 
relapse rates, which remain 10–20% among patients with low IPI risk and 30–50% in 
patients with IPI score >2. Less than 10% of failed patients achieve a long-term DFS 
with salvage conventional-dose chemotherapy, and it is well established that salvage 
treatment in a patients with chemosensitive relapse should, whenever possible, include 
HDC/ASCT (83). A large number of phase-II trials have addressed HDC/ASCT in 
patients with relapsed/refractory DLBCL (84-88), reporting a median 3-year PFS of 
35% and, virtually, all these studies have demonstrated the prognostic importance of 
chemosensitivity before transplantation. The use of HDC/ASCT for relapsed DLBCL 
has been validated after the results of the International PARMA prospective randomized 
trial (82). Two sub-analysis of the PARMA trial, have demonstrated that an IPI score >1 
at relapse and a short time to relapse, defined as TTR < 12 months, correlated with a 
poor survival (89;90). All the available evidence suggests that HDC/ASCT should be 
considered the standard therapy for DLBCL patients with chemotherapy-sensitive 
relapse on a type 1 basis. 
Advances in salvage therapy are needed mainly to overcome resistance to 
chemotherapy, enabling more patients to achieve CR in order to proceed and optimize 
transplantation procedures. Various chemotherapy regimens have been employed for 
DLBCL in the salvage setting. The effectiveness of these regimens has been evaluated 
mainly in non-randomized phase II studies and their outcome is generally expressed in 
terms of ORR and possibility of collecting an adequate number of stem cells for 
transplantation. The combination of rituximab with salvage chemotherapy regimens has 
significantly improved the CR rate also in patients with relapsed/refractory disease. This 
assumption has been demonstrated in a series of 36 patients where the CR rate was 
significantly higher (53% vs. 27% p = 0.01) in the group treated with rituximab and ICE 
(R-ICE) compared with an historical controls of patients treated with ICE alone (91). 
The more robust demonstration of the potential benefits of the addition of rituximab to 
platinum-based salvage regimens has been reported by the HOVON group in a 
prospective randomized trial in 239 patients with relapsed/refractory DLBCL who 
received a salvage regimen consisting of DHAP–VIM–DHAP with or without 
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rituximab followed by HDC/ASCT. A marked difference in favour of the rituximab-
containing regimen in terms of CRR (75% vs. 54%) and 2-year EFS (50% vs. 24%) has 
been observed. However, in this study the prior rituximab use in each group of patients 
was not well described (92). While the benefits of rituximab combined to salvage 
chemotherapy is clearly established, the optimal chemotherapy regimen still needs to be 
determined. Recently, the results of 396 relapsed/refractory DLBCL patients after first-
line therapy enrolled in the CORAL international randomized trial, which compare R-
DHAP to R-ICE followed by HDC/ASCT, have been reported. The ORR was 63%, 
with 38% of CR. There was no difference in terms of ORR between R-ICE (63.5%) and 
R-DHAP (62.8%), in mobilization-adjusted response rate (52% vs. 54%), and in the 3-
year EFS (26% vs. 35%p = 0.6). Fewer serious adverse events were reported in the R-
ICE regimen compared to R-DHAP (93). Of note, the 3-year EFS was significantly 
affected by early relapse (20% vs. 45%, p < 0.0001), by a high IPI risk at relapse (18% 
vs. 40%, p < 0.0001) and by prior first-line treatment with rituximab (21% vs. 
47%,p < 0.0001). Early relapse, IPI at relapse and prior treatment with rituximab have 
been significantly associated with ORR, OS, EFS, and PFS (94). A recent analysis 
performed on the CORAL database showed that R-DHAP was superior to R-ICE in 
patients with ABC-type DLBCL (95). In this context, PET-positive result prior to 
ASCT is associated with a short duration of response and a higher risk of 
relapse (96;97). Thus, the response prior to transplant is highly predictive of the 
outcome and PET scan should be incorporated in the definition of quality of the 
response. 
The use of allogeneic SCT for relapsed/refractory DLBCL is still limited since the 
reasonable good outcome and low toxicity of HDC/ASCT.  
1.6.5. Salvage treatment strategies without transplant 
Because of age or comorbidities not all patients are eligible for a transplant. We can 
assume that about 40–60% of elderly patients with DLBCL treated with R-CHOP will 
be refractory or experience relapse during their clinical course. Effective and less toxic 
chemotherapy approaches are still therefore needed. New chemotherapy drugs or 
biological agents both alone or in combination are also worth considering for this 
specific and broad group of patients. 
 21 
More recently, gemcitabine and oxaliplatin have been shown activity in relapsed or 
refractory DLBCL. In a single arm study involving 46 patients with relapsed DLBCL 
who received rituximab, gemcitabine and oxaliplatin in combination (R-Gem-OX), 38 
patients (83%) responded and 23 (50%) achieved CR by the end of treatment. The 
regimen has been well tolerated but long-term results in patients previously treated with 
rituximab are not satisfactory (98). New biological drugs with different mechanisms of 
action should be encouraged in this unfavourable and frail group of elderly patients. 
1.6.6. Novel approaches to DLBCL 
Several novel agents are undergoing evaluation in DLBCL, as both single agents in the 
relapsed setting or in combination with standard chemotherapy R-CHOP. These agents 
have different activity degrees and some of their mechanisms are incompletely 
understood. These new approaches include immunomodulating agents (IMiDs) such as 
lenalidomide, m-TOR inhibitors as temsirolimus and everolimus, proteasome inhibitors 
as bortezomib, histone deacetylase inhibitors as vorinostat, and anti-angiogenetic agents 
(anti-VEGF) as bevacizumab. 
IMIDs inhibit angiogenesis and tumour necrosis factor (TNF)-alpha, stimulate immune 
responses, alter cytokines and inhibit interleukin-12, affect stromal cells, induce 
apoptosis and inhibit pro-survival factors (Akt). Lenalidomide has been evaluated as 
single agent in a series of 73 relapsed/refractory DLBCL patients with an ORR of 29%. 
Toxicity was mild and mainly haematological (99). In another series of 49 heavily pre-
treated patients with relapse/refractory DLBCL treated with lenalidomide 25 mg daily 
an objective response was observed in 35% of cases, with a 12% CRR (100). On this 
basis, the Fondazione Italiana Linfomi is running a prospective multicenter dose finding 
phase II pilot trial to evaluate efficacy and safety of treatment with lenalidomide plus R-
CHOP21 (LR-CHOP21) for elderly patients with untreated Intermediate-High/high-risk 
IPI, with a MTD of lenalidomide in this combination of 15 mg over 14 days. 
A variety of intracellular oncogenic pathways are potential targets for DLBCL therapy. 
Small molecules can selectively inhibit specific signalling molecules of pathways 
critical for survival of lymphoma cells. The targeting of PI3K/Akt/mTOR pathway 
seems to be a relevant strategy for the treatment of some lymphomas. The exact 
mechanisms of mTOR inhibitors remain unclear, but likely include induction of 
autophagy, anti-angiogenesis, immunoregulation and translation inhibition of cell 
survival proteins (101,102). First-generation mTOR inhibitors were soluble rapamycin 
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derivatives (rapalogs), temsirolimus and everolimus being the better known agents. 
Everolimus has promising single-agent activity in various lymphomas, with an ORR of 
30% in DLBCL (103). This drug is being addressed as maintenance therapy in DLBCL 
in CR after RCHOP in a phase III trial. The strategy of targeting molecules upstream of 
mTOR, such as protein kinase 3 (AKT) and PI3K, is more potent than the use of mTOR 
inhibitors in in vitro studies. Enzastaurin is a selective inhibitor of the PKC and AKT 
pathways known to promote tumour angiogenesis, as well as tumour-cell survival and 
proliferation (104). A phase II trial with oral enzastaurin plus GEMOX is ongoing, 
while preliminary results of a small randomized phase II study suggest a better outcome 
with the combination of R-CHOP-enzastaurin vs. R-CHOP (104). Oral enzastaurin is 
also being tested in DLBCL patients as maintenance after the end of first-line 
chemotherapy in a large international phase III randomized trial. 
Bortezomib is a proteasome inhibitor initially approved for use in multiple myeloma 
and currently under continued investigation in lymphomas, with reasonable response 
rates in mantle cell lymphoma. One postulated mechanism of action in lymphomas is 
the ability of bortezomib to ameliorate molecular dysregulation in NF-κB activation and 
regain cell cycle control. Bortezomib has been safely administered in combination with 
R-CHOP21 to patients with newly diagnosed DLBCL (106). This combination has been 
associated with an ORR of 100% and 86% CRR, with a 2-year PFS of 64% and 2-year 
OS of 70%. Unlike in DLBCL treated with R-CHOP alone, germinal-centre B-cell-like 
and nongerminal-centre B-cell DLBCL subtypes had similar outcomes (106) Moreover, 
some activity in combination with salvage regimens have been reported (107). 
New generation of monoclonal antibodies are currently being investigated to assess 
their activity in DLBCL. Inotuzumab ozogamicin (CMC-544), a humanized anti-CD22 
antibody conjugated to calicheamicin, a potent antitumor antibiotic, demonstrated an 
improved single-agent activity, with 15% ORR in DLBCLs (108). Recently, a new 
humanized anti-CD20 mAb, with high affinity for FcRγIII, named GA101, was 
developed. GA101 demonstrated antibody-dependent complement-mediated 
cytotoxicity and strong caspase-independent apoptosis activity upon CD20 
binding (109). An European randomized phase-III trial finalized to compare rituximab 
vs. GA101 in association with standard chemotherapy CHOP in DLBCL is ongoing. 
Preliminary results of ongoing phase I and II clinical trials suggest a relevant activity 
with blinatumomab, a bispecific T-cell engager targeting CD19 and CD3 antigens, in 
relapsed or refractory follicular lymphoma and mantle cell lymphoma suggesting this 
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antibody should be assessed also in DLBCL. One advantage of blinatumomab is the use 
of activated CD3+ T cells to kill the malignant CD19+ B cells bypassing specialized 
effectors (110). 
Histone deacetylases (HDACs) inhibitors play a role in regulating cell-cycle 
progression, survival, angiogenesis and immunity and constitutes a new group of drugs 
with demonstrated activity in some lymphoma categories, mostly cutaneous T-cell 
lymphoma and Hodgkin lymphoma. Expression of HAT1 and HDAC1, molecules that 
play a critical role in lymphomagenesis, is high in DLBCL, and it seems to be correlated 
with poor survival (111). These observations seem to suggest that HDACs inhibitors 
may play a therapeutic role also in DLBCL and constitute the background of ongoing 
prospective trials. Since HDACs modulate a variety of survival factors, the most 
probable use of their inhibitors will be in combination with other biological agents. 
In the next future, the combination of these new biological drugs with conventional 
chemo-immunotherapy should be incorporated in the first-line management of DLBCL 
patients in attempt to increase the response rate and lymphoma-free survival. 
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2. OVERVIEW OF HYSTONE DEACETYLASE INHIBITORS 
 
2.1. Overview of Panobinostat (LBH589) 
 
Histone deacetylases (DACs) are enzymes that regulate chromatin structure and 
function through the removal of acetyl groups from lysine residues of core histones. In 
particular DACs target lysine groups on chromatin, transcription factors and various 
non-histone proteins such as p53, tubulin, HSP90 and Rb.  Hystone deacetylase 
inhibitors (DACi) are a group of molecules able to induce rapid histone 
hyperacetylation and chromatin remodelling yielding to the activation or repression of 
genes regulating apoptosis, proliferation, differentiation, angiogenesis, immune 
responses. Panobinostat is a DACi belonging to cinnamic hydroxamic acid class of 
compounds. It is a highly potent class I/II pan-DAC inhibitor that has shown anti-tumor 
activity in pre-clinical models and in cancer patients. Panobinostat is formulated as an 
oral capsule and a solution for intravenous (IV) injection. Both the oral and IV 
formulations are currently being investigated in ongoing phase I and phase II studies in 
advanced solid tumors and haematological malignancies. 
 
2.2. Proposed mechanism of anticancer activity of DAC inhibitors 
 
Alterations in chromosome structure play critical roles in the control of gene 
transcription. These epigenetic alterations include modification of histones and others 
proteins by acetylation and/or phosphorylation. Normally, these modifications are 
balanced finely by maintenance of levels of deacetylase enzymes in check. The levels of 
these enzymes are altered and may be elevated in tumor cells, thereby causing an 
imbalance and thus leading to a closed and tightly bound chromatin structure. This leads 
to an inability of the transcription initiation factors to bind to the promoter regions on 
the DNA resulting in the modulation of the expression of a subset of genes, including 
the tumor suppressor genes, in a coordinated fashion. Several tumors suppressor genes 
associated with the malignant phenotype are repressed by epigenetic mechanisms in 
sporadic cancers. Thus, therapy with DAC inhibitors, which leads to an opening of the 
chromatin structure thereby allowing re-initiation of the transcription mechanisms, may 
alter tumor phenotype and inhibit growth in such tumors. Tumor growth inhibition and 
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apoptosis in response to DACi treatment may also be mediated by changes in 
acetylation of non-histone proteins (e.g., HSP90, p53, HIF-1α, α-tubulin). For example, 
the chaperone protein HSP90 has been shown to be acetylated in cells treated with 
DACi (112-114). Acetylation of HSP90 inhibits its ability to bind newly synthesized 
client proteins, thus preventing proper client protein folding and function. In the 
absence of HSP90 function, misfolded proteins are targeted for degradation in the 
proteasome. Many proteins that require HSP90 association are critical to cancer cell 
growth, including ErbB1, ErbB2, AKT, Raf, KDR, and BCR-ABL. Acetylation of 
HSP90 in cells treated with DACi inhibits the chaperone function of HSP90, leading to 
degradation of the client proteins and eventually cell death. The potential clinical utility 
of the use of DACi in cancer therapy was first suggested by the activity of sodium 
phenylbutyrate against acute promyelocytic leukemia (115). Vor nost t (Zol nz ™)   n 
orally administered, structurally-related DACi has been reported to have single-agent 
activity in cutaneous T-cell lymphoma (CTCL), diffuse large cell lymphoma, and head 
and neck cancer (116;117). Vorinostat was approved by the FDA for the treatment of 
cutaneous manifestations of CTCL in patients with progressive, persistent or recurrent 
disease (118). Similar activity has been reported in clinical studies with other DACi, 
including IV romidepsin (119), which was approved for the treatment of patients who 
have received at least one prior systemic therapy in CTCL in November 5, 2009. 
 
2.3. Preclinical studies 
2.3.1. In vitro study 
Preclinical activity of panobinostat was tested against a broad array of tumor cell lines, 
 n lu  n  t   Ho  k n‟s lymp om    ll l n s RPMI6666  HD-MY-Z, and L428. These 
cells were incubated in culture with different concentrations of panobinostat to 
determine the effect of the compound on the proliferation and viability of the cells. 
Consistent with the proposed mechanism of action for panobinostat, tumor cells 
exposed to panobinostat for 2 hours or more demonstrated increased levels of histone-
H3 and -H4 acetylation lasting up to 72 hours. The HL cell lines exhibited extreme 
sensitivity to panobinostat with IC50 values ranging from 200 picomolar to 50 
nanomolar; these concentrations can easily be achieved in the plasma of patients with 
doses that have been safely administered. Panobinostat induced cell death in 
transformed cells while, in similar conditions, induced growth arrest in normal cells. 
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A recent study (120) highlighted that the inhibition of histone deacetylase overcomes 
rapamycin-mediated resistance in diffuse large B cell lymphoma (DLBCL) by 
inhibiting Akt signaling through mTORC2. In this study, increasing doses of 
panobinostat (5-100 nM) suppressed the survival of each cell line in a dose-dependent 
manner. The anti neoplastic effect of ex vivo panobinostat was recently investigated in 
cells from biopsies of patients with various B-NHL, including 5 DLBCL. Fifteen out of 
16 patient samples analyzed showed moderate to high sensitivity to panobinostat;  
Western blots of lymphocytes treated with panobinostat showed increased acetylation of 
histone H4 compared to untreated cells (121).  
 
2.3.2 In vivo studies 
The activity of panobinostat was assessed in several in vivo tumor models including 
BT474 (breast cancer) and CWR22Rv1 (prostate adenocarcinoma) mouse models. 
Panobinostat treated tumors regressed during the time of treatment whereas the vehicle 
treated tumors grew. Additional data and experiments, including those for 
hematological malignancy cell lines and xenograft models, are described in the 
panobinostat IB. 
 
2.4. Clinical studies 
 
2.4.1 Pharmacokinetics 
Panobinostat is rapidly absorbed with a median Tmax reached within 1 hour after oral 
administration. The absolute oral bioavailability of panobinostat is approximately 30%. 
The compound can be administer regardless of food intake as the variability and overall 
systemic exposure remained unchanged in patients taking panobinostat with or without 
food (122). AUC increased linearly and proportionally with doses up to 50 mg. In vitro 
plasma protein binding of panobinostat (mainly to albumin) is moderate (89.6% at 
37°C) and independent of concentration. Elimination half-lives averaged 15 hours. 
Steady state is achieved by the third dose following days 1, 3, and 5 (TIW) weekly 
(QW) dosing. The metabolism of panobinostat is extensive and several metabolic 
pathways are involved including reduction, hydrolysis, oxidation, and glucuronidation 
processes. It is a substrate of cytochrome P450 3A4 (CYP3A4) with minor involvement 
of CYP2D6 and 2C19 as well as an inhibitor of CYP2D6. Panobinostat and its 
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metabolites (~at least 40 metabolites in circulating plasma) were nearly equally excreted 
in urine and bile/feces of patients. 
 
2.4.2 Safety 
Pooled safety data from patients with advanced hematological malignancies or solid 
tumors or lymphomas, enrolled in three Phase I and six Phase II studies of single-agent 
oral panobinostat have recently been reviewed. Data cut-off date was April 8, 2009 for 7 
studies and Sept 24, 2009 and Oct 3, 2009 for two other studies, respectively. The 
overall population was divided in patients with solid tumors or lymphomas (N = 266) 
and patients with all other hematological malignancies (N = 293). Furthermore, data 
was analyzed separately for patients who received panobinostat three times a week 
every week (N = 226) and three times a week every other week (N = 40) 
For the every week dosing schedule: 
• T rombo ytop n    s t   most  ommon   v rs   v nt r port  ;  t  s not    t  ll  os  
levels with increasing frequency and severity with an increase in dose. In the clinical 
trials, thrombocytopenia has been successfully managed with dose interruption, dose 
reduction and platelet transfusion. Considering this common occurrence of 
thrombocytopenia, a guidance has been provided regarding exclusion of patients from 
the study entry if the baseline platelet count is below 100 x10
9
/L and dose delay or 
reductions be instituted for low counts during the study. 
• Gastrointestinal events such as diarrhea and nausea are also commonly reported but 
are primarily of grade 1 or 2 severity. 
• Anemia and neutropenia are noted primarily at the 40 mg dose and since this dose has 
b  n stu     mostly  n p t  nts w t  Ho  k n‟s lymp om   t   un  rly n    s  s  m y 
have a role in the occurrence of this event. 
• F t  u  o   r    1  n  2 s v r ty  s r ported across all doses but it does not seem to 
have an augmented incidence with the increasing in dosage. The underlying reason for 
fatigue is currently unknown. 
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Most common adverse events reported when panobinostat is administered three 
times every week (N=226) 
 
 
For the every other week dosing schedule, the number of patients treated is small and so 
direct comparisons cannot be made between the 2 schedules. The following findings can 
still be noted: 
• In t  s sm ll numb r o  p t  nts    t  u   s t   most common adverse event, although 
the events are primarily of mild severity. 
• W  l  t rombo ytop n    s  ommonly s  n  t    r qu n y o   r    3 or 4  v nts  s 
much lower than that observed with the every week schedule 
• Ot  r   v rs   v nts  r   ll o   r de 1 and 2 severity. 
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Since thrombocytopenia is the most common adverse event observed with panobinostat, 
additional analysis have been conduced that suggest: 
• T    r qu n y o   r    3/4 t rombo ytop n    n    n   w s   n r lly      r w t  
panobinostat weekly dosing, compared to dosing every other week 
• Thrombocytopenia was more frequently observed in patients with hematologic 
malignancies  
• For p t  nts w t  sol   tumors or lymp om s  n w or wors n n   r    3 or 4 
thrombocytopenia onset often occurred wit  n t     rst 2 w  ks  or ≥40 m / os   v ry 
week schedule 
• M    n t m  to t rombo ytop n   w s   n r lly s ort r  n t   w  kly s    ul s t  n 
that in every other week schedules, especially for patients with solid tumors and 
lymphomas 
• The median duration of thrombocytopenia was relatively short (~8 days) and similar 
across both schedules 
• In   n r l   s support   by t   pr  l n   l   n  n s   v ry ot  r w  k  os n   pp  rs 
to be associated with lower hazard rate of new or worsening grade 3 or 4 
thrombocytopenia compared to the weekly dosing schedule. 
• T    r qu n y o   os    justm nts   nt rrupt ons   n    s ont nu t on  u  to 
thrombocytopenia was generally higher with panobinostat weekly dosing, compared to 
every other week dosing at comparable dose levels, which suggests better tolerability of 
every other week dosing with oral panobinostat. 
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Most common adverse events reported when panobinostat is administered three 
times every other week (N=40) 
 
2.5. Clinical activity in hematological malignancies  
 
The safety and tolerability of panobinostat has been explored in several hematological 
malignancies.  
Giles et al. described 15 patients with acute myeloid leukemia, acute lymphocytic 
leukemia or myelodisplastic syndrome who were treated with increasing doses of 
panobinostat (4,8 – 14 mg/m2). Four dose-limiting toxicities (grade 3 QTcF 
prolongation) were observed; other toxicities included nausea (40%), diarrhea (33%), 
vomiting (33%), hypokalemia (27%), loss of appetite (13%), and thrombocytopenia 
(13%). In 8 of 11 patients with peripheral blasts, transient blast cell reductions occurred 
with a rebound following the treatment period (123).  
Another large study was performed to evaluate panobinostat in patients with advanced 
hematologic malignancies including Hodgkin lymphoma, non-Hodgkin lymphoma, or 
multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, chronic 
idiopathic myelofibrosis, acute lymphoblastic leukemia, chronic myelomonocytic 
leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia. 128 pts were 
 nroll  : t   most  ommon  r    3/4 AEs (≥10%) w r  t rombo ytop n   (43%)  
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neutropenia (22%), febrile neutropenia (20%), fatigue (20%), and anemia (11%). Anti-
tumor activity was observed in a group of 13 response-evaluable patients with 
relapsed/refractory Hodgkin lymphoma, in 26 patients with acute myeloid leukemia and 
in patients with other hematologic malignancies (124).  
Another study investigated safety and toxicity of panobinostat in resistant-refractory 
patients with mycosis fungoides and Sezary syndrome. Panobinostat was administered 
at the dose of 20 mg on days 1, 3, and 5 weekly until disease progression or intolerance. 
Diarrhea, thrombocytopenia, fatigue, asthenia, hyper-triglyceridaemia, nausea and 
pruritus were the most common toxicities, while no QTc prolongation >500 ms were 
evidenced. Three patients achieved a partial response and 4 patients maintained a stable 
disease (125).  
Another study tested panobinostat in the same setting of patients: 10 patients with 
cutaneous T-cell lymphoma received 20 mg of panobinostat on days 1, 3 and 5 of each 
week on a 28-day cycle. Patients attained a CR (2), a PR (4), achieved stable disease 
with ongoing improvement (1), or progressed on treatment (2). The treatment was 
globally well tolerated, and the microarray data showed that the majority of genes 
involved in this neoplasm was repressed after treatment (126). Panobinostat use was 
investigated in myelofibrosis too. Thirteen patients have been treated, including 10 
patients with idiopathic myelofibrosis and 3 pts with post-polycythemic disease. Among 
12 patients evaluable for response, one has demonstrated a partial response, including 
 n 85% r  u t on  n spl  n s z ; t r   p t  nts   monstr t    l n   l b n   t l st n  ≥8 
weeks: reduction in spleen size, transfusion independence and improvement in other 
disease-related symptoms were observed. Four patients had stable disease (127).  
In another study, panobinostat was implied in 12 patients with primary myelofibrosis 
and post-polycythemia/essential thrombocythemia myelofibrosis: two patients had a 
greater than 50% reduction in spleen size. One of these patients has also had a 
significant reduction in RBC transfusion requirements and has complete resolution of 
splenomegaly at 7 months.  Two patients experienced clinical improvement and 4 
patients had stable disease. Thrombocytopenia was the only DLT observed; the most 
common non-hematologic AEs noted were grade 1 nausea, fatigue, diarrhea and 
musculoskeletal pain (128).  
Two studies evaluated the possibility to imply panobinostat in chronic myeloid 
leukemia (CML); the first study investigated the efficacy and safety of panobinostat in 
patients with chronic phase CML who had received at least 2 prior BCR-ABL tyrosine 
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kinase inhibitors. 29 patients were enrolled, and no major cytogenetic response 
(MCyR), but 1 complete hematologic response (CHR) with eradication of the T315i 
mutation were observed (129). The second study used panobinostat in patients  in 
accelerated phase or blastic crisis stage of a Ph positive CML. A total of 27 patients 
were enrolled, but  no MCyR or CHR were observed (130). A more recent report, 
analyzed safety and tolerability of panobinostat given in combination with imatinib in 
CML patients. Five patients were enrolled: DLT (grade 3 thrombocytopenia) was 
observed in one patient. Toxicities included thrombocytopenia (Grade 3 [n=2]; grade 1-
2 [n=4]), hypophosphatemia (grade 3 [n=1]; grade 2 [n=2]), fatigue (grade 1 [n=3]), 
hypocalcemia (grade 1 [n=2] and grade 1-2 GI symptoms (diarrhea [n=2]; nausea [n=3]; 
anorexia [n=2]; vomiting [n=3]; constipation [n=1]), notably, no significant QTc 
prolongation was observed on intensive. Q-PCR analyses showed reduction in BCR-
ABL levels in 2 patients, with a patient that reached undetectable BCR-ABL after 3 
months of treatment (131). 
Panobinostat was largely tested also in multiple myeloma. In a first study, 38 patients 
with advanced refractory multiple myeloma were treated with 20 mg of this drug. 
Overall, panobinostat was well tolerated; mild or moderate level of nausea, as well as 
fatigue/asthenia, occurred in half of the patients. One clinical durable response (very 
good partial response – VGPR) and 3 stable disease observations longer than 3 months 
occurred in 3 patients (132). Another study explored maximum-tolerated dose (MTD), 
safety, tolerability, pharmacokinetic/pharmacodynamic profiles, and preliminary 
efficacy of the combination therapy including panobinostat and bortezomib in patients 
with advanced refractory multiple myeloma. A total of 29 patients have been enrolled 
into four dosing cohorts: encouraging clinical efficacy was observed in all four cohorts, 
with 14 responders (PR or better) in 28 evaluable patients (50%), including 4 with 
immunofixation negative CR. Four additional patients achieved minor responses, 
resulting in 64% overall response rate. Responses were also seen in the subset of 
patients refractory to prior bortezomib, suggesting a strong clinical correlation for 
synergism of the panobinostat plus bortezomib combination. Overall, the combination 
of panobinostat and bortezomib was safe and tolerated; hematologic adverse events 
(AEs) have been frequent, including grade 3/4 thrombocytopenia (25), neutropenia (18), 
and anemia (6): non-hematologic AEs included: diarrhea (18), fever (15), nausea (14), 
fatigue (14), and asthenia (11) (133).  A recent study investigated safety, tolerability, 
PK/PD, and preliminary efficacy of combination treatment of panobinostat, 
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lenalidomide and dexamethasone. Twenty-two patients with relapsed or relapsed 
refractory MM were treated in three dose levels; the only study drug related SAE was 
fever in two patients. Safety and early efficacy have not been reported yet (134). 
In vivo studies indicated that panobinostat is well tolerated and induces clinical
 
responses in several hematological malignancies including HL and CTCL. On these 
grounds several new clinical studies are now ongoing to test the clinical activity of 
panobinostat in different clinical setting. Some in vitro studies suggest the possible 
therapeutic activity also in patients with aggressive B cell lymphoma.  
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3. A PHASE II STUDY OF ORAL PANOBINOSTAT IN 
ADULT PATIENTS WITH DIFFUSE LARGE B-CELL 
LYMPHOMA RELAPSED/REFRACTORY AFTER HIGH-
DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM 
CELL TRANSFUSION (ASCT) OR NOT ELEGIBLE FOR 
ASCT. 
 
3.1. Purpose/Rationale 
 
Treatment of patients with DLBCL who relapse after ASCT or result non eligible for 
ASCT because of refractory disease, age or co-morbidities represents an unmet medical 
need. The use of DACis is approved in cutaneous T-cell lymphoma, but the efficacy in 
other lymphomas, particularly B-cell Non-Hodgkin's lymphoma, remains to be 
established. Even if the therapeutic activity of panobinostat in DLBCL is not yet 
defined, some preclinical data suggests the possible of this agent for these diseases.  The 
rationale of this study is to investigate the therapeutic activity of panobinostat in 
patients with DLBCL in order to consider the possible future use of this agent either in 
combination with standard therapy or as maintenance therapy.  
 
3.2. Objectives 
Primary objective 
1. To explore the anti-tumor activity of panobinostat in term of overall response 
(OR) at the end of the induction phase (i.e. month 6 from the beginning of panobinostat) 
Secondary objectives 
1. To explore the anti-tumor activity of panobinostat in terms of Complete 
Response (CR)  
2. To assess the time to response (TTR) 
3. To evaluate Progression Free Survival (PFS) 
4. To assess the safety and tolerability of panobinostat 
5. To evaluate the Overall Survival (OS) 
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Exploratory objectives 
1. To study the impact of pharmacogenetics in predicting the response to 
panobinostat  
2. To stu y t    mp  t o   mmuno  sto   m   l p tt rns  n  p t  nt‟s sp       
gene expression and response to panobinostat  
3. To assess the correlation between "telomeric asset" and response to panobinostat 
 
Endpoints 
• CT scan evaluation to assess the response rate and for monitoring progression 
according to the Cheson 1999 response criteria; the reason to adopt the Cheson 1999 
criteria is because of the high number of radiological evaluation indicated in the study, 
particularly during the induction phase (every two months). Overall response is defined 
as CR or PR 
• Safety: Common Terminology Criteria for Adverse Events (CTCAE Version 
4.0) 
• SNPs genotypic variant (pharmacogenetics) 
• Immunophenotypic analysis on tissue-microarray (to assess whether the 
distinction of DLBCL subtypes according to the supposed histogenesis GBC-type vs. 
ABC-type vs. NC performed by immunohistochemistry has prognostic value in patients 
treated with DACi) 
• Gene expression analysis (to identify molecular signatures related to treatment 
response/resistance; to test previously identified molecular profiles associated to 
resistance to conventional chemotherapy in patients receiving DACi) 
• Assessment of telomere-deregulation by assessing the following parameters: 
whole telomere lenght by southern blot and STELA (single telomere length analysis), 3' 
overhang size by G-tail telomere hybridization protection assay (Gt-telomere HPA), and 
expression of telomere-related proteins. 
• The Progression Free Survival (PFS) is defined as the time from enrolment to 
disease progression or death from any cause 
• The time to response is defined as the time from enrolment to OR 
• The Overall Survival (OS) is defined as the time from enrolment to death from 
any case 
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3.3. Study design 
 
This will be a multi-center, italian, open-label, phase II study. All participating centers 
are members of FIL (Italian Lymphoma Foundation) with specific expertise in the 
management of patients with lymphoma.  
The trial is conducted according to the optimal two-stage design of Simon with alpha 
0.05 and beta 0.10, considering the following two hypotheses: first a response rate (RR) 
less than 10% is of no further interest; and second, an RR 30% is clinically meaningful. 
In the initial stage, 18 patients have to enter onto the study. I  l ss t  n 3 r spons s  (≤2 
in 18) will be observed, the trial would be terminated. Otherwise, accrual will continue 
to a total of a maximum of 35 patients. At the end of the trial, if 6 or fewer responses 
will o  ur  mon  t   35 p t  nts (≤6 in 35), it will be concluded that the regimen is not 
worthy of further investigations for that group of patients.  
The treatment is divided in three phases: induction phase (course 1 to 6), consolidation 
phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for 
any reason). This choice is made in order to have a well defined initial period of 
response evaluation (induction phase) and to understand the possible impact of 
subsequent continuous administration of panobinostat in terms of improvement of 
response (consolidation phase) and response duration (maintenance phase).  This study 
is expected to start in January 2011. The last patient is expected to be enrolled at the end 
of December 2011. Considering a possible treatment duration of 24 months, this trial is 
due to be completed by December 2013. Approximately 15 centers are involved. 
 
3.4. Inclusion/Exclusion criteria 
 
3.4.1 Inclusion criteria: 
1. P t  nt      s ≥ 18 y  rs 
2. P t  nt   s  n E st rn Coop r t v  On olo y Group (ECOG) p r orm n   st tus o  ≤ 
2 
3. Patient  has a history of DLBCL according to the WHO classification 
4. Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first 
line regimen, standard second line therapy (DHAP, ESHAP, ICE or similar salvage 
regimens) inclusive ASCT 
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5. Patient has progressive disease after receiving at least CHOP-R or CHOP-R like first 
line regimen and is not considered eligible for intensive salvage therapy including 
ASCT because of age, co-morbidities, impossibility to perform ASCT 
6. Patient undergoes at baseline new lymph node or other pathologic tissue biopsy for 
confirmation of diagnosis and biologic studies; bone marrow biopsy is not adequate for 
this purpose and should be performed only for staging. Patients with primary 
refractoriness, not eligible for intensive salvage therapy including ASCT, who 
performed a previous biopsy with stored frozen material 6 months or less before 
enrolment into the study do not have to repeat a new biopsy   
7. Patient has at least one site o  m  sur bl  no  l   s  s   t b s l n  ≥ 2.0  m  n t   
longest transverse diameter as determined by CT scan (MRI is allowed only if CT scan 
can not be performed). Note: Patients with bone marrow involvement are eligible, but 
this criteria alone should not be used for disease measurement 
8. Patient has the following laboratory values (labs may be repeated, if needed, to obtain 
acceptable values before screen fail):  
• Absolut  n utrop  l  ount (ANC) ≥ 1.5 x 109/L [SI un ts 1.5 x 109/L] 
• Pl t l t  ount ≥ 100 x 109/L 
• Serum potassium, magnesium, phosphorus, sodium, total calcium (corrected for 
serum albumin) or ionized calcium within normal limits (WNL) for the institution  
• S rum  r  t n n  ≤ 1.5 x ULN 
• S rum b l rub n ≤ 1.5 x ULN (or ≤ 3.0 x ULN     p t ent has Gilbert syndrome) 
• AST/SGOT  n /or ALT/SGPT ≤ 2.5 x upp r l m t o  norm l (ULN) or ≤ 5.0 x 
ULN if the  transaminase elevation is due to disease involvement 
9. Clinically euthyroid. Note: Patients are permitted to receive thyroid hormone 
supplements to treat underlying hypothyroidism 
10. Written informed consent was obtained from the patient prior to any study-specific 
screening procedures 
11.  Patient has the ability to swallow capsules or tablets 
12.  Practice acceptable birth control 
 
3.4.2 Exclusion criteria 
1. Patient has a history of prior treatment with a DAC inhibitors including panobinostat 
2. Patient will need valproic acid for any medical condition during the study or within 5 
days prior to the first panobinostat treatment 
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3. Patient has been treated with monoclonal antibody therapy (e.g., rituximab or anti 
CD-30 antibody, etc.) within 4 weeks of start of study treatment 
4. Patient has been treated with any other anti lymphoma therapy within 3 weeks of start 
of study treatment 
5. Patient is using any anti-cancer therapy concomitantly 
6. Patient has been treated with > 5 prior systemic lines of treatment 
7. P t  nt   s r    v   pr or r    t on t  r py ≤ 4 w  ks or l m t      l  r   ot  r py ≤ 
2 weeks prior to start of study treatment  
8. Patient treated with allogeneic hematopoietic stem cell transplant with active 
progressive cGVHD; patient has received DLI ≤ 6 w  ks pr or to st rt o  stu y 
treatment; patient is planned to receive DLI  
9. P t  nt   s     story o   not  r m l  n n y ≤ 3 y  rs b  or  stu y  ntry  w t  t   
exception of non-melanoma skin cancer and carcinoma in situ of uterine cervix 
10. Patient has a history of CNS involvement with lymphoma 
11. Patient has impaired cardiac function including any of the following: 
• Compl t  l  t bun l  br n   blo k or us  o    p rm n nt   r     p   m k r  
congenital long QT syndrome, history or presence of ventricular tachyarrhythmias, 
clinically significant resting bradycardia (<50 beats per minute), QTcF > 450 msec on 
screening ECG, or right bundle branch block + left anterior hemiblock (bifascicular 
block) 
• Pr s n   o  unst bl   tr  l   br ll t on (v ntr  ular heart rate >100 bpm). Patients with 
stable atrial fibrillation are allowed in the study provided they do not meet the other 
cardiac exclusion criteria 
• Pr v ous   story  n  n  p  tor s or   ut  MI w t  n 6 mont s 
• Con  st v     rt    lur  (N w York Heart Association functional classification III-IV) 
12. Patient has any other clinically significant heart disease (e.g., uncontrolled 
hypertension) 
13. Patient has an impairment of gastrointestinal (GI) function or GI disease that may 
significantly alter the absorption of panobinostat (e.g., ulcerative disease, uncontrolled 
nausea, vomiting, diarrhea, malabsorption syndrome, obstruction, or stomach and/or 
small bowel resection) 
14. P t  nt   s unr solv      rr o   ≥  r    2 
15. Patient has any other concurrent severe and/or uncontrolled medical condition(s) 
(e.g., uncontrolled diabetes mellitus, active or uncontrolled infection, chronic 
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obstructive or chronic restrictive pulmonary disease including dyspnoea at rest from any 
cause) that could cause unacceptable safety risks or compromise compliance with the 
protocol 
16. Patient has a known history of HIV seropositivity  
17. Patient has active HBV hepatitis. The following categories of patients HBV positive 
but with non evidence of active hepatitis may be considered for the study and treated 
with panobinostat (see also Section 8.12):  
• patient is HBsAg + with  HBV DNA < 2000 UI/ml (inactive carriers); HBV 
DNA > 2000 UI/ml is criteria of exclusion 
• patient is HBsAg – HBsAb + 
• patient is HBsAg – but HBcAb + 
18. Patients with HCV active hepatitis are excluded from the study. Patient with no 
evidence of active hepatitis and/or advanced chronic liver disease according to liver 
biopsy or fibro-scan evaluation may be included into the study (see also Section 8.13) 
19. Patient is using medications that have a relative risk of prolonging the QT interval 
or of inducing Torsade de Pointes, where such treatment cannot be discontinued or 
switched to a different medication prior to starting study drug 
20. Women who are pregnant or breast feeding or women of childbearing potential 
(WOCBP) not willing to use a double method of contraception during the study and 3 
months after the end of treatment. One of these methods of contraception must be a 
barrier method. WOCBP are defined as sexually mature women who have not 
undergone a hysterectomy or who have not been naturally postmenopausal for at least 
12 consecutive months or had menses any time in the preceding 12 consecutive months. 
WOCBP must have a negative serum pregnancy test at baseline 
21. Male patient whose sexual partner(s) are WOCBP who are not willing to use a 
double method of contraception, one of which includes a condom, during the study and 
for 3 months after the end of treatment  
22. Patient does not have before entering into the study a new lymph node or other 
pathologic tissue biopsy for confirmation of diagnosis and biologic studies; bone 
marrow biopsy is not adequate for this purpose and should be performed only for 
staging. 
 
 
 40 
3.5. Dose, regimen, treatment cycle 
The duration of a treatment course will be 28 days. The first dose of panobinostat in 
course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 
days later.  
Induction phase (course 1 to 6) 
Patients will receive panobinostat for 6 courses (1 course = 28 days). Response 
assessment will be performed every two courses until the end of the induction phase. 
Patients with responsive (complete or partial response) or stable disease during each 
assessment will complete the induction phase. 
Consolidation phase (courses 7 to 12) 
Consolidation phase includes courses from 7 to 12 (1 course = 28 days).  Response 
assessment will be performed every three courses until course 12. Patients with 
responsive (complete or partial response) or stable disease after the consolidation phase 
will continue therapy according to the maintenance phase. 
Maintenance phase (from course 13 to the end of therapy) 
Patients will continue therapy with panobinostat until disease progression, intolerability, 
withdrawal of consent and/or if the investigator determines that further therapy is not in 
t   p t  nt‟s b st  nt r st ( . .   u  to non-compliance, toxicity etc.). Response 
assessment will be performed every three courses until course 36. For patients still in 
therapy with panobinostat after course 36, the subsequents response assessments will be 
performed according to each institutional policy. 
Treatment 
Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week 
(QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), 
as part of a 4 week (28 days) treatment cycle. 
Oral panobinostat capsules should be administered as follows: 
• P t  nts s oul  b   nstru t   to t k  t   r t r   t m s   w  k or l  os  o  p nob nost t 
at the same time on each dosing day (e.g. day 1, 3, and 5). Doses should be separated by 
a minimum of 30 hours 
• P t  nts s oul  b   nstru t   to t k  t      ly  os  o  or l p nob nost t    t r   
minimum 2-hour fast and should continue to fast for 2 hours post dose. Each dose of 
panobinostat should be taken with a glass (approximately 240 mL) of non-carbonated 
water. Patients should be instructed to swallow the capsules whole and not chew them  
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• I  vom t n  o  urs  ur n  t    ours  o  tr  tm nt  t  n no r -dosing of the patient is 
allowed before the next scheduled dose  
 • P t  nts must  vo    r p  ru ts   r p  ru t ju     S v ll  (sour) or n  s  n  S v ll  
orange juice during the entire study period. 
Duration of treatment with panobinostat 
Patients may continue treatment with panobinostat until the patient experiences 
unacceptable toxicity that precludes any further treatment, and/or the investigator 
  t rm n s t  t  urt  r  t  r py  s not  n t   p t  nt‟s b st  nt r st ( . .   u  to non-
compliance, toxicity etc.).  
Patients who discontinue treatment with panobinostat (non-compliance, toxicity or start 
of new anti cancer therapy) remain into the study and are evaluated for follow up. 
Patients who experience disease progression must be follow up for vital status until 
death or at least  36 months. 
Patients who withdraw consent must be permanently discontinued from the study.   
 
3.6. Study drug discontinuation 
Patients who discontinue study drug for any reason should be scheduled for a visit as 
soon as possible and all of the assessments listed for the final visit should be performed. 
All patients must have evaluations for 28 days after the last dose of study treatment, 
including the monitoring of adverse events and concomitant medications (including 
anti-neoplastic ther py). I   ppl   bl    ny   v rs   v nt m rk    s „ ont nu n ‟  s o  
the last dose of study medication must be followed at least once per week for at least 4 
weeks until resolution of the event, return to baseline status, or clinical stability is 
reached. At a minimum, all patients who discontinue study treatment, including those 
who refuse to return for a final visit, will be contacted for safety evaluations during the 
28 days following the last dose of study drug. Patients lost to follow up should be 
recorded as such on the CRF. Patients who discontinue study treatment for reasons 
other than progression should continue to have tumor assessments according to the 
protocol until disease progression. If patients refuse to return for these visits or are 
unable to do so, the patient should be considered off-study, and a Study Evaluation 
Completion form should be completed. If possible, survival information must be 
registered at the end of the study. 
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3.7. End of treatment 
Patients may voluntarily withdraw from the study or be dropped from it at the discretion 
of the Investigator at any time. If such withdrawal occurs, or if the patient fails to return 
 or v s ts  t   Inv st   tor must   t rm n  t   pr m ry r  son  or   p t  nt‟s pr m tur  
withdrawal from the study and record this information on the End of Treatment CRF. 
Therapy may be interrupted for one of the following reasons:  
• Adverse event(s) 
• Abnormal laboratory value(s) 
• Abnormal test procedure result(s) 
• Protocol deviation 
• Subject withdrew consent 
• Lost to follow-up 
• Administrative problems 
• Death 
• Initiation of new cancer therapy 
• Disease progression 
• T    nv st   tor   t rm n s t  t  urt  r t  r py  s not  n t   p t  nt‟s b st  nt r st 
(e.g., due to non-compliance, toxicity etc.) 
For patients who are lost to follow-up, the investigator should show "due diligence" by 
documenting in the source documents steps taken to contact the patient, e.g., dates of 
telephone calls, registered letters, etc. Patients must be followed for 28-days post-last 
treatment of study drug for toxicity. All patients who have been discontinued from 
study drug treatment for any reason other than progression should continue to have 
tumor assessments until the end of the study or PD. Once a patient discontinues study 
drug administration and no additional study assessments will be performed other than 
survival information, a Study Evaluation Completion form should then be completed. 
The reasons for study evaluation completion may include the following: 
• Protocol deviation 
• Subject withdrew consent 
• Lost to follow-up 
• Administrative problems 
• Death 
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• New cancer therapy 
• Disease progression 
 
 3.8. Histopatology and gene expression profiling studies 
3.8.1. Background 
Diffuse large B cell lymphoma (DLBCL) is currently regarded in the WHO 
classification as a neoplasm of large B lymphoid cells with nuclear size equal to or 
exceeding normal macrophage nuclei or more than twice the size of a normal 
lymphocyte, that has a diffuse growth pattern. Morphological, biological and clinical 
studies have subdivided DLBCL into morphological variants, molecular and 
immunophenotypic subgroups and distinct disease entities. However, a large number of 
cases remain that may be biologically heterogeneous, but for which there are no clear 
and accepted criteria for subdivision. These are classified as DLBCL, not otherwise 
specified (NOS). Noteworthy, recent gene expression profile (GEP) studies 
demonstrated the existence of at least two main molecular subgroups of DLBCL, 
namely germinal centre B-type (GCB-type) and activated B-cell type (ABC-type) 
provided with significantly different prognosis (135-138). In particular, such tumours 
are classified according to the expression of genes reflecting their cell of origin 
(germinal centre vs. late germinal centre/plasmablast (139)), proliferation rate and host 
immune response to the tumour. Of note, the molecular classification has been 
demonstrated to predict the clinical outcome for patients treated with CHOP or R-
CHOP (and similar) regimes, and, intriguingly, target therapies specific for each 
subtypes have been recently proposed, such as NFKB inhibition in ABC-cases (140). 
On the other hand, a discrete fraction of cases, still remain unclassifiable basing on 
GEP, not belonging to either one subgroup (termed type 3 or unclassified). 
In the clinical practice, due to the frequent unavailability of fresh/frozen pathological 
material and the relatively high costs necessary for GEP analysis, surrogate markers for 
DLBCL classification have been required. In particular, in the last few years, several 
attempts have been made to design diagnostic algorithms based on 
immunohistochemical studies (141-143). However, it was clear that although such 
systems provided useful prognostic information, they were not able to definitely 
recapitulate the molecular classification. Thus, a better definition of the 
immunohistochemical diagnostic markers is warranted. 
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3.8.2. Aims of the study 
1) To define the molecular subgroups of DLBCL 
a. Basing on GEPs 
b. Basing on novel immunohistochemical patterns 
2) To identify possible molecular signatures associated with panobinostat 
resistance/sensitivity 
a. Reflecting the current molecular classification (GCB vs. ABC vs. type 3) 
b. Reflecting different molecular features 
3.8.3. Samples and Methods  
Sample collection. Formalin-fixed paraffin embedded (FFPE) tissue blocks will be 
centralized at the Unit of Hematopathology, Molecular Pathology Laboratory, 
D p rtm nt o  H  m tolo y  n  On olo y “L.  n  A. S rà nol ” (To t   Att nt on o  
Prof. Stefano A. Pileri/Dr. Pier Paolo Piccaluga). When available, frozen tissue will be 
collected as well. FFPE tissues will be shipped at room temperature; when available, 
fresh tissue will be first cryopreserved and then shipped in dry ice (and delivered within 
24 hours).  
Tissue microarray analysis. Tissue microarrays (TMAs) will be constructed as 
previously described (31). Three different cores for each case will be considered. 
Immunohistochemistry will be carried out in order to 1) confirm the diagnosis of 
DLBCL; 2) to investigate the ability of a newly developed immunohistochemical 
pattern to discriminate GCB, ABC and type 3 DLBCLs; 3) to investigate whether the 
immunophenotypic profile correlates with clinical outcome in patients receiving 
HDACi. The immunohistochemical analysis will include the antibodies directed against 
the following antigens: CD10; CD20; CD79a; CD30; BCL2; BCL6; IRF4; IRTA1; 
CD138; LMO2; JAW1; PAG; GCET; BLIMP1; VpreB3; FOXP1; HGAL. 
In addition, ISH and FISH/CISH will be performed on TMAs in order to assess the 
prevalence and the clinical impact of EBV integration and translocations involving 
BCL2, BCL6 and MYC, respectively. 
Gene expression profile analysis. Gene expression profile (GEP) analysis will be 
performed on pathologic specimens by using the DASL technology and Illumina DNA-
m  ro rr ys. Tot l RNA w ll b   xtr  t   by us n  t   R  ov rAll™ Tot l Nu l    
Acid Isolation Kit for FFPE (Applied Biosystems/Ambion, Austin, TX USA) and 
converted to cDNA according to a standard protocol (Illumina, USA). Finally, after 
incubation with the whole genome DASL assay pool (DAP), and enzymatic extension 
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and ligation steps, the nucleic acids will be hybridized to whole genome gene 
expression BeadChips and then scanned on a BeadArray
TM
 Reader using BeadScan 
software. Analysis of GEPs will be then carried on by using GenSpring 10.3/11 as well 
Partek suite. Supervised, unsupervised analyses as well as principal component analysis 
(PCA), GSEA and cell type classification will be performed as previously described 
(144). Non parametric rather then parametric tests will be applied, if indicated, 
according to the number of cases included in each subgroup. 
 
3.9. Statistical methods and data analysis 
 
3.9.1 Sample size 
The sample size is established according to evaluation of the primary endpoint. The trial
 
is conducted according to the optimal two-stage design of Simon
 
with alpha 0.5 and 
beta 0.10, considering the following two hypotheses: first a response rate (RR) less
 
than 
10% is of no further interest; and second, an RR 30% is
 
clinically meaningful. In the 
initial stage, 18 patients have
 
to entered onto the study. If no more than 2 responses ( 2 
in 18) will be observed, the trial would
 
be terminated. Otherwise, accrual will continue 
to a total
 
of a maximum of 35 patients. At the end of the trial,
 
if 6 or fewer responses 
will be occurred among the 35 patients, it will be concluded that the regimen
 
is not 
worthy of further investigations for that group of patients.
 
The decision to proceed to 
stage 2 will be based on Investigator assessment of tumor response by clinical 
evaluation and CT scan. 
Since the biologic studies have only an explorative purpose the sample size is not 
calculated according to these analysis. 
 
3.9.2. Efficacy 
Primary efficacy endpoint is the objective response rate as determined by evaluation of 
CT scans/MRI for response by clinical site investigator. The response criteria according 
to Cheson 1999 will be adopted.  
On these grounds:  
 Complete response (CR) requires the following:  
1. Complete disappearance of all detectable clinical and radiographic evidence of 
disease and disappearance of all disease-related symptoms if present before therapy, and 
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normalization of those biochemical abnormalities (eg, lactate dehydrogenase definitely 
assignable to NHL  
2. All lymph nodes and nodal masses must have regressed to normal size ( 1.5 cm in 
their greatest transverse diameter for nodes > 1.5 cm before therapy). Previously 
involved nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before 
treatment must have decreased to  1 cm in their greatest transverse diameter after 
treatment, or by more than 75% in the sum of the products of the greatest diameters 
(SPD) 
3. The spleen, if considered to be enlarged before therapy on the basis of a CT scan, 
must have regressed in size and must not be palpable on physical examination. 
However, no normal size can be specified because of the difficulties in accurately 
evaluating splenic size. For instance, spleens thought to be of normal size may contain 
lymphoma, whereas an enlarged spleen may not necessarily reflect the presence of 
lymphoma but variations in anatomy, blood volume, the use of hematopoietic growth 
factors, or other causes. The determination of splenic volume or splenic index by CT 
scan are cumbersome and not widely used. Any macroscopic nodules in any organs 
detectable on imaging techniques should no longer be present. Similarly, other organs 
considered to be enlarged before therapy due to involvement by lymphoma, such as 
liver and kidneys, must have decreased in size  
4.  If the bone marrow was involved by lymphoma before treatment, the infiltrate must 
be cleared on repeat bone marrow aspirate and biopsy of the same site. The sample on 
which this determination is made must be adequate (20 mm biopsy core). Flow 
cytometric, molecular, or cytogenetic studies are not considered part of routine 
assessment to document persistent disease at the present time  
 CR/unconfirmed (CRu) includes those patients who fulfill criteria 1 and 3 
above, but with one or more of the following features:  
1. A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that 
has regressed by more than 75% in the SPD. Individual nodes that were previously 
confluent must have regressed by more than 75% in their SPD compared with the size 
of the original mass 
2. Indeterminate bone marrow (increased number or size of aggregates without 
cytologic or architectural atypia) 
 Partial response (PR) requires the following:  
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1.  50% decrease in SPD of the six largest dominant nodes or nodal masses. These 
nodes or masses should be selected according to the following features: (a) they should 
be clearly measurable in at least two perpendicular dimensions, (b) they should be from 
as disparate regions of the body as possible, and (c) they should include mediastinal and 
retroperitoneal areas of disease whenever these sites are involved 
2. No increase in the size of the other nodes, liver, or spleen  
3. Splenic and hepatic nodules must regress by at least 50% in the SPD  
4. With the exception of splenic and hepatic nodules, involvement of other organs is 
considered assessable and not measurable disease  
5. Bone marrow assessment is irrelevant for determination of a PR because it is 
assessable and not measurable disease; however, if positive, the cell type should be 
specified in the report, eg, large-cell lymphoma or low-grade lymphoma (ie, small, 
lymphocytic small cleaved, or mixed small and large cells)  
6. No new sites of disease  
 Stable disease is defined as less than a PR (see above) but is not progressive 
disease (see below).  
 Relapsed disease (CR, CRu) requires the following:  
1. Appearance of any new lesion or increase by  50% in the size of previously involved 
sites  
2.  50% increase in greatest diameter of any previously identified node greater than 1 
cm in its short axis or in the SPD of more than one node  
 Progressive disease (PR, non-responders) requires the following:  
1.  50% increase from nadir in the SPD of any previously identified abnormal node for 
PRs or non responders  
2. Appearance of any new lesion during or at the end of therapy  
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3.9.3. Response Assessment 
Response is currently assessed on the basis of clinical, radiological, and pathologic (ie, 
bone marrow) criteria.  
1. CT scans remain the standard for evaluation of nodal disease. Thoracic, abdominal, 
and pelvic CT scans are recommended even if those areas were not initially involved 
because of the unpredictable pattern of recurrence  
2. A bone marrow aspirate and biopsy should only be performed to confirm a CR if they 
were initially positive or if it is clinically indicated by new abnormalities in the 
peripheral blood counts or blood smear 
3. A PET or a CT-PET scan is requested in patients attaining CR or PR every 6 months  
 
3.9.4. Statistical analysis 
Descriptive statistics and their 95% confidence intervals will be used to summarize the 
activity and the safety endpoints. Time to event variables will be analysed using the 
Kaplan-Meier method. A subgroup analysis for patients with DLBCL relapsed and/or 
refractory and those not eligible for ASCT will be performed, if the number of patients 
in each group will be sufficient. Subgroup analysis for ancillary studies 
(pharmacogenetic studies and histopatology and gene expression profiling studies) will 
be analysed with explorative purpose.  
 
3.9.5. Safety assessment 
The severity of adverse events will be graded on a scale of 1 to 5 according to the 
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
version 3.0 (NCI CTCAE).  
 
3.10. Preliminary results 
 
Thirty-five patients, 21 males (60%), were enrolled between June 2011 and March 
2014. Clinical characteristics were: median age 73 (range 65-75), stage IV in 18 (55%), 
B-symptoms in 9 (28%), increased LDH in 24 (69%), high-intermediate or high 
International Prognostic Index (IPI) in 18 (51%). Patients received a median of 2 prior 
lines of therapy (range 1-4).  
At the end of induction phase, 7 responses (20%) were observed, including 4 CR (11%), 
while 28 patients (80%) discontinued treatment due to progressive disease (PD) in 21 
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(60%) or adverse events  in 7 (20%). Median TTR in 9 responders was 2.6 months 
(range 1.8-12). With a median follow up of 6 months (range 1-34), the estimated 12 
months PFS and OS were 27% and 30.5%, respectively (Fig.2 and 3) 
 In univariate analysis, favourable IPI score and cutaneous involvement at enrollment 
showed a trend toward a higher ORR (p=0.007 and 0.061, respectively); 
pharmacogenetics, immunohistochemical and gene expression profile studies are still 
ongoing.  
No toxic deaths were reported; 18 patients died, 17 due to lymphoma progression and 
one for allogeneic transplant related complications, performed after PD. Grade 3-4 
thrombocytopenia and neutropenia were the most common toxicities (in 29 (83%) and 
12 (34%) patients, respectively), while grade 3-4 extra-hematological toxicity included 
diarrhoea in 4 (12%), infectious complications in 1 (3%) and supraventricular 
arrhythmia in 2 patients (6%). 
 
 
   
 
 
Fig. 2 and 3: the estimated 12 months PFS and OS were 27% and 30.5% respectively. 
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4. CONCLUSION 
 
The prognosis of patients with DLBCL relapsed and/or refractory to CHOP-R first line 
therapy is dismal. High dose therapy and autologous stem cell transplant (ASCT) is an 
active rescue therapy in nearly 50% of patients with chemo-sensitive disease. Therapy 
of patients who relapse after ASCT or result non eligible for ASCT because of 
refractory disease, age or co-morbidities, represents an unmet medical need. Novel 
treatment strategies are needed in such patients with refractory or recurrent lymphoma. 
There are multiple new agents that are currently being evaluated for the treatment  of 
patients with lymphoma (146,147). However, when these compounds are tested in 
unselected patients with relapsed lymphoma, they typically produce low response rates 
with short response duration.  
Histone deacetylases (DACs) are involved in chromatin structure regulation and 
function. Treatment with DACs inhibitors leads to the activation or repression of genes 
regulating apoptosis, proliferation, differentiation, angiogenesis, immune responses. 
These agents resulted to be active for the treatment of T and B-cell lymphoma and other 
haematological malignancies. Previous in vitro studies underlined the possible 
pathophysiological role of DACs in diffuse large B-cell lymphoma (DLBCL).  
FIL-PanAL10 (NCT01523834) is a phase II, prospective multicenter trial of the 
Fondazione Italiana Linfomi (FIL). In this study we evaluate the therapeutic activity and 
safety of Panobinostat, a potent pan-DACs inhibitor, in patients with relapsed or 
refractory (R/R) DLBCL. Exploratory objectives evaluate the predictive role of 
pharmacogenetics, immunohistochemical and specific gene expression in relation to the 
response to Panobinostat are still ongoing; for this aim a new lymph node or other 
pathologic tissue biopsy is requested before starting treatment.    
and to evaluate a possible relationships between response and any biological features. 
The results of this study indicate that Panobinostat might be remarkably active in some 
patients with R/R DLBCL, showing durable CR. Feasibility was impaired by relevant 
hematological toxicity, mainly frequent and dose limiting grade 3-4 thrombocytopenia. 
Data that will be obtained from biological exploratory studies could hopefully be useful 
to better address the use of Panobinostat in peculiar subsets of patients. 
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